-Reuters
Amyris Highlights In-Vivo Results In Study Of Its Licensed RNA Vaccine Through Intranasal Delivery
Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced